Cetirizine ophthalmic - Nicox

Drug Profile

Cetirizine ophthalmic - Nicox

Alternative Names: AC-170; cetirizine ophthalmic solution, 0.24% - Nicox; ZERVIATE

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Aciex Therapeutics
  • Developer NicOx
  • Class Acetic acids; Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Allergic conjunctivitis

Highest Development Phases

  • Preregistration Allergic conjunctivitis

Most Recent Events

  • 09 Mar 2017 Cetirizine ophthalmic - Nicox is available for licensing in USA as of 09 Mar 2017. http://www.nicox.com/
  • 10 Oct 2016 Nicox Ophthalmics receives complete response letter from the FDA for cetirizine ophthalmic in Allergic conjunctivitis
  • 21 Jun 2016 Nicox Ophthalmics has two patent protection for cetirizine opthalmic in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top